Venus Remedies soars on securing marketing authorizations for Docetaxel, Gemcitabine in Europe
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Venus Remedies is currently trading at Rs. 418.00, up by 8.40 points or 2.05% from its previous closing of Rs. 409.60 on the BSE.
The scrip opened at Rs. 412.40 and has touched a high and low of Rs. 429.50 and Rs. 406.95 respectively. So far 25177 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 429.60 on 05-Jan-2024 and a 52 week low of Rs. 145.00 on 08-Feb-2023.
Last one week high and low of the scrip stood at Rs. 429.50 and Rs. 397.55 respectively. The current market cap of the company is Rs. 544.50 crore.
The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 1.59% and 56.65% respectively.
Venus Remedies has secured new marketing authorizations for Docetaxel in concentrations of 160MG/8ML, 20MG/1 ML and 80MG/4ML (Single Vial), as well as Gemcitabine 1G from Malta, Europe. These approvals signify its commitment to expanding its pharmaceutical portfolio and market presence.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.
